<DOC>
	<DOCNO>NCT02169089</DOCNO>
	<brief_summary>Atherosclerotic disease , harden artery , characterize thicken arterial wall due fatty deposit wall inflammation wall artery . High cholesterol , high blood pressure , diabetes , obesity genetics play important role develop clinical symptom atherosclerosis disease . The complication advance atherosclerosis chronic , slowly progressive cumulative , result heart attack , stroke and/or death blockage artery . This study do assess effectiveness Spironolactone therapy slow worsen atherosclerotic disease ( harden artery ) aorta ( large vessel come heart ) compare placebo ( look alike sugar pill ) . This check compare therapy magnetic resonance imaging ( MRI ) picture aortic wall . Spironolactone FDA approve drug use treat heart failure management hypertension ( high blood pressure ) , study use another unapproved reason . In study , would like evaluate effect Spironolactone people diabetes atherosclerotic disease .</brief_summary>
	<brief_title>Mineralocorticoid Receptor Antagonism Clinical Evaluation Atherosclerosis Trial</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>1 . Male female patient &gt; 45 year able provide inform consent ( female must either postmenopausal one year , surgically sterile , use effective contraception . Oral contraceptive disallow . 2 . Patients Type II Diabetes HbA1c ≤ 8.0 stable antiglycemic regimen may include oral and/or injectable therapy ( GLP1/Insulin etc. ) . No new drug allow . Changes dose glycemic regimen allow course trial felt clinically appropriate . 3 . In addition Type II diabetes , 2 follow additional high risk feature : 1 . Established cardiovascular disease [ previous MI , CVA PAD OR prior intervention/surgery condition 2 . Age &gt; 45 year 3 . Evidence proteinuria ( Urine Albumin/Creatinine Ratio &gt; 30 ) urine specimen within 12 month 4 . Evidence document retinopathy 5 . LVH Echocardiogram 12lead EKG 6 . Family history premature CAD 4 . LDL cholesterol &lt; 130 mg/dL Plasma triglycerides &lt; 300 mg/dl 5 . Blood pressure ≤145/90 mm Hg visit 2 ( see TABLE 2 ) 6 . Patients must ACE and/or ARB therapy statin therapy plan dose adjustment . 7 . Willing sign inform consent form participate research trial 1 . Uncontrolled hypertension ( SBP &gt; 160 and/or DBP &gt; 95 mmHg visit 0 ( screen ) SBP &gt; 145 mm Hg visit 2 ) . 2 . GFR ( MDRD ) &lt; 40 Visit 1 . 3 . Hyperkalemia define serum K+≥ 5.0 meq/L visit 0 ( screen ) . If K+ &gt; 5.5 meq/L time point dose escalation patient terminate . If K 5.05.4 meq/L , Epl dose decrease K+ rechecked . If K+ continue ≥5.5 patient discontinue trial . There specific K+ management protocol Human Subjects section . K+ value management blind study investigator . 4 . Contraindications MRI ( metallic implant , severe claustrophobia ) . 5 . Acute coronary syndrome , Transient ischemic attack , CVA critical limb ischemia last 6 month coronary/peripheral revascularization within last 3 month . 6 . Evidence secondary form hypertension . 7 . Initiation new therapy statin , ACEI/ARB , antioxidant , CCBs , diuretic , β blocker . 8 . Initiation new therapy GLP1 agonists Liraglutide , Exenatide etc . 9 . Type I diabetes mellitus 10 . Known contraindication , include history allergy Epl 11 . Any surgical medical condition might alter pharmacokinetics drug . 12 . Concurrent potentially life threaten arrhythmia symptomatic arrhythmia . 13 . Significant hyponatremia define Na &lt; 130 meq/L . 14 . History prior malignancy include leukemia lymphoma ( basal cell skin cancer , cure squamous cell cancer localize Prostate cancer ) . 15 . History severe , lifethreatening disease . 16 . Any surgical medical condition place patient high risk derive his/her participation study , likely prevent patient comply requirement . 17 . History drug abuse within last 2 year , noncompliance unwillingness/inability consent .</criteria>
	<gender>All</gender>
	<minimum_age>46 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>